These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants. Pałucha A; Pilc A Pol J Pharmacol; 2002; 54(6):581-6. PubMed ID: 12866712 [TBL] [Abstract][Full Text] [Related]
44. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Serretti A; Benedetti F; Zanardi R; Smeraldi E Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1074-84. PubMed ID: 15939518 [TBL] [Abstract][Full Text] [Related]
45. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Wong ML; Licinio J Nat Rev Drug Discov; 2004 Feb; 3(2):136-51. PubMed ID: 15040578 [TBL] [Abstract][Full Text] [Related]
46. Exploring the multifocal role of phytoconstituents as antidepressants. Behl T; Rana T; Sehgal A; Sharma N; Albarrati A; Albratty M; Makeen HA; Najmi A; Verma R; Bungau SG Prog Neuropsychopharmacol Biol Psychiatry; 2023 Apr; 123():110693. PubMed ID: 36509251 [TBL] [Abstract][Full Text] [Related]
48. Current therapy and future treatment strategies for depression (Paris, January 2003). Moret C J Psychopharmacol; 2003 Sep; 17(3):337-41. PubMed ID: 14513927 [No Abstract] [Full Text] [Related]
49. Phosphodiesterase genes and antidepressant treatment response: a review. Esposito K; Reierson GW; Luo HR; Wu GS; Licinio J; Wong ML Ann Med; 2009; 41(3):177-85. PubMed ID: 18932104 [TBL] [Abstract][Full Text] [Related]
50. [Biologic markers and prediction of response to treatment in depression]. Uytdenhoef P; Linkowski P; Mendlewicz J Acta Psychiatr Belg; 1982; 82(3):229-42. PubMed ID: 6187184 [No Abstract] [Full Text] [Related]
51. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. Blier P; de Montigny C; Chaput Y J Clin Psychopharmacol; 1987 Dec; 7(6 Suppl):24S-35S. PubMed ID: 3323264 [TBL] [Abstract][Full Text] [Related]
53. [Biochemical aspects of using antidepressants in late middle age and the elderly (review)]. Burchinskiĭ SG Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(4):607-14. PubMed ID: 6134411 [No Abstract] [Full Text] [Related]
54. From pharmacogenetics to imaging pharmacogenetics: elucidating mechanisms of antidepressant response. Brandl EJ; Walter H Pharmacogenomics; 2017 Jul; 18(10):927-930. PubMed ID: 28639501 [No Abstract] [Full Text] [Related]
55. Restoring value to stalled Phase II compounds: the case for developing a novel compound for depression using pharmacogenetics. Reed C; Kalnik M; Rakin K; Athanasiou M; Judson R Pharmacogenomics; 2005 Mar; 6(2):95-100. PubMed ID: 15882128 [No Abstract] [Full Text] [Related]
57. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. Goodman WK; Charney DS J Clin Psychiatry; 1985 Oct; 46(10 Pt 2):6-24. PubMed ID: 3900056 [TBL] [Abstract][Full Text] [Related]
58. [Neurobiological mechanisms of depression and antidepressant therapy]. Shishkina GT; Dygalo NN Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(2):138-52. PubMed ID: 20469588 [TBL] [Abstract][Full Text] [Related]
60. [Rational use of antidepressants in general medicine]. Verbanck P; Cnockaert P Rev Med Brux; 1996 Sep; 17(4):224-9. PubMed ID: 8927850 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]